Search Results

You are looking at 1 - 10 of 116 items for :

  • "novel therapy" x
  • All content x
Clear All
Full access

Paul D. Harker-Murray, Lauren Pommert, and Matthew J. Barth

), relatively few are being tested in pediatric patients. Selection of novel therapies for pediatric clinical trials will likely be derived from clinical trials that are successful in adults ( Table 3 ). Table 2. Novel Agents and Targets in Non-Hodgkin Lymphoma

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

Cancer ; 2008 : 200 – 213 . 2 Jemal A Siegel R Ward E . Cancer Statistics, 2009 . CA Cancer J Clin 2009 ; 59 : 225 – 249 . 3 Kumar SK Rajkumar SV Dispenzieri A . Improved survival in multiple myeloma and the impact of novel

Full access

Kenneth C. Anderson

neuropathy. Now, however, we have the ability to diagnose patients before the development of these clinical sequelae, and to evaluate the ability of novel therapies to delay or even prevent the development of these complications. Based on retrospective

Full access

Paul G. Richardson, Teru Hideshima, Constantine Mitsiades, and Kenneth C. Anderson

Despite advances in the first-line treatment of multiple myeloma, almost all patients eventually relapse, become chemoresistant, and die of the disease. Improved understanding of potential myeloma targets and molecular mechanisms of drug resistance, along with the development and clinical investigation of targeted antitumor agents, have led to new strategies for the treatment of relapsed myeloma. The proteasome inhibitor bortezomib, the immunomodulatory agent thalidomide, and the thalidomide derivative lenalidomide, are all recently approved treatment options for myeloma. Single-agent bortezomib has been shown to provide significantly greater efficacy than high-dose dexamethasone, and bortezomib has also been investigated in combination with other agents commonly used to treat myeloma, including thalidomide and lenalidomide, with high overall and complete response rates. The safety profile of bortezomib has been well characterized, and side effects have been shown to be generally predictable and manageable, including in high-risk and elderly patients and those with renal impairment. Thalidomide has been extensively studied alone and in combination in patients with relapsed myeloma, demonstrating substantial efficacy, and is therefore widely used in this setting. The toxicity profile is dose- and duration-linked, with lower doses appearing to be better tolerated. Lenalidomide plus dexamethasone has been shown to have significantly greater activity than dexamethasone alone in the relapsed setting, with impressive duration of disease control. Other combinations are also under investigation, with promising early results. Some aspects of the toxicity profile appear significantly reduced relative to thalidomide, although myelosuppression is increased. Other novel therapies at earlier stages of development are being studied and may provide further options in the treatment of relapsed myeloma. This review focuses on results from key phase II and III trials of bortezomib, thalidomide, and lenalidomide alone or in combination, and their emerging role in improving outcomes.

Full access

Marjorie G. Zauderer and Lee M. Krug

relevant based on the biology of this disease. Furthermore, it would be optimal to create a new research infrastructure to facilitate the study of novel therapies in MPM through maximizing the use of limited resources, both financial and patient population

Full access

Ashraf Badros

/Autologous Stem Cell Transplantation (cont.) Emerging data suggest that novel therapies and combinations may ameliorate the adverse influence of these poor-risk features, underscoring the importance of including genetics into risk-stratification schemes

Full access

Lina Jansen, Daniel Boakye, Elizabeth Alwers, Prudence R. Carr, Christoph Reissfelder, Martin Schneider, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner

the data in our study were not sufficient to perform such analysis. Conclusions In this cohort of patients with CRC recruited in a population-based setting in Germany, we found higher rates of administration of novel therapies such as targeted

Full access

Paul G. Richardson, Jacob P. Laubach, Robert L. Schlossman, Constantine Mitsiades, and Kenneth Anderson

, Love G, McCullagh E, Sandifer S. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008;12(3 Suppl):29–36; permission conveyed through

Full access

Lainie Martin and Russell J. Schilder

Although significant improvements in standard therapy for ovarian carcinoma have been made over the past decade, current treatment is limited by the development of resistance to cytotoxic chemotherapy, and most women ultimately die of the disease. New knowledge of the biology of ovarian cancer has led to the identification of potential molecular targets that are differentially expressed in normal cells versus cancer cells, and advances in pharmacology have led to the development of novel agents that work differently from traditional cytotoxic chemotherapy by exploiting these targets. Many of these agents are being evaluated in clinical trials. This article discusses molecular targets that are important in ovarian carcinoma, including angiogenesis, tyrosine kinases, mitogen-activated protein kinases, and phosphatidylinositol-like kinases such as mammalian target of rapamycin, and the proteosome. This article reviews novel non-cytotoxic agents that target these pathways and are currently being evaluated in ovarian carcinoma treatment.